More Effort Needed to Recruit Minorities to Phase 3 Clinical Trials, MS Expert Says
Because multiple sclerosis (MS) presentation and progression course can be very different between people of African ancestry and Caucasians,…
Articles by Alice Melão, MSc
Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says
OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble…
FDA Asked to Approve Diroximel Fumarate as Oral Treatment for Relapsing MS
Alkermes filed a request for the approval of diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis (MS) with…
Ocrevus Now Available Through NHS Scotland to Treat RRMS
Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients…
WUSTL Team Receives $6.3 Million Grant to Develop PET Scan Tracers
The Washington University School of Medicine in St. Louis (WUSTL) will create a new research center to investigate and advance…
Gilenya Now Approved in Europe to Treat Children, Adolescents with RRMS
Gilenya (fingolimod) was approved by the European Commission as a treatment for children and adolescents, ages 10 to 17,…
Artificial Intelligence May Help Reduce Dosage of Gadolinium in MRIs, Researchers Suggest
Artificial intelligence can help reduce the amount of gadolinium used as a contrast agent in MRI (magnetic resonance imaging)…
Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces
BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the…
FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says
The U.S. Food and Drug Administration (FDA) has approved a generic version of Aubagio (teriflunomide) tablets at the 7…
Protein Produced by Common Gut Bacteria Can Trigger Autoimmunity, Study Suggests
Bacteria that reside in human gut may trigger autoimmune reactions by producing human-like proteins that mimic a naturally occurring and…
Mavenclad Named ‘Rapid Uptake Product’ in UK with Goal of Speeding Its Availability in NHS
Mavenclad (cladribine tablets, 10 mg) was one of the seven medicinal and medical technology products selected by the…
Stem Cells from MS, Parkinson’s Patients Voyaging to Space Station to Study Disease Impact on Brain in Microgravity
Stem cells from patients with Parkinson’s disease and primary progressive multiple sclerosis (PPMS) are soon to voyage into space, and…
Enzyme Produced by Gut Bacteria Linked to T-cell Attacks on Myelin in Study
An enzyme produced by bacteria in the gut was seen to activate immune cells linked to the development and progression…
#ECTRIMS2018 – Role of Brain Atrophy in MS Progression Poorly Understood by Patients, MSAA Survey Finds
Although brain atrophy — the loss of brain volume — is an increasingly important measure in multiple sclerosis trials and…
#ECTRIMS2018 – Additional Analysis on Ozanimod Demonstrates Its Potential to Treat Relapsing MS
Additional analysis of clinical data from Celgene’s investigational agent ozanimod continues to demonstrate its potential to benefit patients…
#ECTRIMS2018 – MS Patients More Prone to Health Problems Before, After Diagnosis, Study Suggests
Patients with multiple sclerosis (MS) are more likely to experience health problems before they receive their formal diagnosis, as well…
#ECTRIMS2018 — Merck KGaA to Present Latest Data on MS Portfolio
Merck KGaA will present the latest advances made on several of its therapies aiming to treat multiple sclerosis (MS)…
FDA, EMA Agree to Review Novartis Therapy Siponimod to Treat SPMS
Novartis is seeking U.S. and European approval of its investigational oral agent siponimod to treat adults with secondary…
UVA Scientist Awarded $5.6M by NIH to Further Study Lymph System and Brain Connection
Jonathan Kipnis, the researcher who discovered that lymphatic vessels are important mediators of the underlying molecular mechanism of multiple…
Nyrada Identifies Novel IRAK4 Inhibitors that May Prevent Neuroinflammation
Nyrada, a subsidiary company of Noxopharm, discovered a set of novel compounds that can cross the blood-brain barrier…
Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report
Eighteen months after its entrance into the U.S. market, Genentech’s Ocrevus (ocrelizumab) has become the monoclonal antibody of…
Mavenclad Approved to Treat Highly Active Relapsing MS Patients in Ireland
Adults in Ireland with highly active relapsing multiple sclerosis (MS) now can be treated with Mavenclad (cladribine tablets, 10…
Quanterix’s Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression
Quanterix’s ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament…
Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study
Results from a first-in-human study assessing the safety and early activity of PRN2246 confirmed that the oral compound can reach…
FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS
Seven years after it first denied the request, the U.S. Food and Drug Administration accepted for review EMD Serono’s…
Oral DMTs Still Common 1st Therapy for New MS Patients but Ocrevus Having Impact, Market Report Says
Oral disease-modifying therapies (DMTs) are the most common first choice of treatment for people newly diagnosed with multiple sclerosis (MS)…
Enzyme Key to Myelin Renewal and Nerve Cell Health Possibly Identified in Study
A better understanding of the processes behind a continual and healthy renewal of myelin — the fatty, protective substance wrapping…
Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports
Cladridine may be effective in preventing disability progression and reducing damage to nerve cells in people with progressive forms of multiple sclerosis…
Common Anti-Parasitic Agent Eases Motor Symptoms, Aids Remyelination in MS Mouse Model
A common anti-parasitic agent showed a potential to prevent inflammation and to promote nerve cell recovery — remyelination — in…
No Risk of MS Found in GlaxoSmithKline Vaccine for Swine Flu, Canadian Study Says
Protecting the public against an outbreak like the swine flu using GlaxoSmithKline‘s vaccine Arepanrix — or a similar vaccine with an AS03 adjuvant…